Kayexalate (Sodium Polystyrene Sulfonate) Dosing
For adults, administer 15 grams orally one to four times daily (total daily dose 15-60 grams) or 30-50 grams rectally every 6 hours; for pediatric patients, use 0.5-1 g/kg orally based on severity of hyperkalemia. 1
Adult Dosing
Oral Administration
- Standard dose: 15 grams (four level teaspoons) administered 1-4 times daily
- Total daily range: 15-60 grams depending on severity and resistance of hyperkalemia 1
- Preparation: Suspend each dose in 3-4 mL of liquid per gram of resin (water or syrup)
- Timing: Administer at least 3 hours before or after other oral medications; patients with gastroparesis require 6-hour separation 1
- Position: Patient must be upright during administration 1
Rectal Administration
- Dose: 30-50 grams every 6 hours 1
- Preparation: Administer as warm (body temperature) emulsion in 100 mL aqueous vehicle, flush with 50-100 mL fluid
- Retention: Keep retained as long as possible, then follow with cleansing enema using non-sodium containing solution (up to 2 liters) 1
Pediatric Dosing
Use 0.5-1 g/kg orally based on hyperkalemia severity 2. In the largest pediatric study (156 patients, mean age 6.8 years), the mean effective dose was 0.64 ± 0.32 g/kg, with 91% administered orally 2. The nadir potassium occurred at approximately 17 hours post-dose 2.
Dose-Response Relationship
The evidence demonstrates a clear dose-response pattern in adults 3, 4:
- 15 grams: Reduces potassium by approximately 0.4-0.8 mEq/L 3, 4
- 30 grams: Reduces potassium by approximately 0.7-0.95 mEq/L 3, 4
- 60 grams: Reduces potassium by approximately 0.9-1.4 mEq/L 3, 4
For mild hyperkalemia (K+ 5.0-5.9 mEq/L), a single 60-gram oral dose is most effective with minimal hypokalemia risk 4. However, 50% of patients receiving only 15 grams remained hyperkalemic versus none with 60 grams 4.
Critical Safety Considerations
Absolute Contraindications
- Obstructive bowel disease
- Neonates with reduced gut motility
- Hypersensitivity to polystyrene sulfonate resins 1
High-Risk Situations Requiring Extreme Caution
Do NOT use in patients with 5, 1:
- No bowel movement post-surgery
- History of constipation, impaction, or inflammatory bowel disease
- Ischemic colitis or vascular intestinal atherosclerosis
- Previous bowel resection or obstruction
Serious Adverse Events
Kayexalate carries significant mortality risk 5. The 2021 Mayo Clinic guideline highlights:
- Cases of fatal GI injury including intestinal necrosis and colonic necrosis 5
- Doubling of risk for hospitalization due to serious GI adverse events 5
- Overall mortality rate of 33% reported 5
- Never use with sorbitol - this combination is particularly dangerous 1, 6
Recent population-based data confirms 1.94-fold increased risk of serious GI events within 30 days (intestinal ischemia being most common) 6.
Clinical Efficacy Limitations
Kayexalate should NOT be used for emergency treatment of life-threatening hyperkalemia due to delayed onset of action 1. The onset is variable (several hours to days) 5, making it inappropriate for severe acute hyperkalemia requiring >25% potassium reduction or patients at high risk for cardiac arrhythmias 2.
The evidence base is remarkably weak - only one small 7-day randomized controlled trial (N=33) supports its use 5. In that study, 30 grams daily reduced potassium by 1.04 mEq/L versus placebo 5.
Monitoring Requirements
- Serum potassium: Monitor closely for severe hypokalemia 1
- Magnesium and calcium: Check regularly as Kayexalate is nonselective and binds these cations 5, 1
- Bowel function: Discontinue immediately if constipation develops 1
Practical Considerations
- Prepare suspension fresh and use within 24 hours 1
- Do NOT heat - this alters resin exchange properties 1
- One level teaspoon = approximately 3.5 grams Kayexalate + 15 mEq sodium 1
- Significant sodium load: 1500 mg sodium per 15-gram dose 5
Contemporary Context
The 2021 Mayo Clinic guideline strongly suggests considering newer potassium binders (patiromer or sodium zirconium cyclosilicate) over Kayexalate 5. These agents have faster onset (1-7 hours vs hours-to-days), no reported fatal GI injuries, and better evidence supporting their use 5. Kayexalate use varies dramatically by country (42% in France to <1% in UK, Spain, Japan), reflecting international uncertainty about its risk-benefit profile 5.